Pulse Biosciences (NASDAQ:PLSE) Sets New 12-Month High – Time to Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares hit a new 52-week high on Tuesday . The company traded as high as $50.90 and last traded at $49.3210, with a volume of 21355 shares changing hands. The stock had previously closed at $49.13.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PLSE. Wall Street Zen downgraded shares of Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Mizuho set a $45.00 price objective on Pulse Biosciences in a research report on Monday, August 10th. Finally, Needham & Company LLC initiated coverage on Pulse Biosciences in a report on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Pulse Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $45.25.

Pulse Biosciences Trading Down 1.8%

The company has a fifty day moving average price of $34.48 and a two-hundred day moving average price of $26.66. The firm has a market capitalization of $3.33 billion, a PE ratio of -40.76 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. As a group, equities research analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Institutional Investors Weigh In On Pulse Biosciences

Several hedge funds have recently modified their holdings of PLSE. Osterweis Capital Management Inc. purchased a new stake in shares of Pulse Biosciences in the second quarter valued at about $28,000. BNP Paribas Financial Markets grew its position in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the period. Tower Research Capital LLC TRC increased its holdings in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Pulse Biosciences by 44.0% in the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after buying an additional 1,372 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new stake in shares of Pulse Biosciences during the 2nd quarter valued at approximately $241,000. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.